FABLE THERAPEUTICS
LIVE

Serial Number

98849309

Owner

Fable Therapeutics, Inc.

Attorney

Aaron D. Hendelman

Filing Date

Nov 12, 2024

Add to watchlist:

No watchlists yet
View on USPTO

FABLE THERAPEUTICS Trademark

Serial Number: 98849309

FABLE THERAPEUTICS is a trademark filed by Fable Therapeutics, Inc. on November 12, 2024. The trademark is classified under Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Fable Therapeutics, Inc.

One Kendall Square, B200
Cambridge, MA 02139

Entity Type: 03

Trademark Details

Filing Date

November 12, 2024

Registration Date

Not Registered

Published for Opposition

October 7, 2025

Goods & Services

Research and development of biological and pharmaceutical drugs to treat diseases utilizing a proprietary drug discovery platform; drug discovery services; pharmaceutical research and development services; providing online non-downloadable computer software for collecting, analyzing, reporting, and tracking data and information in the fields of biotechnology and pharmaceuticals; software as a service (SAAS) services featuring software for collecting, analyzing, reporting, and tracking data and information in the fields of biotechnology and pharmaceuticals; providing online non-downloadable computer software for use in generating, analyzing, and accessing data via artificial intelligence and machine learning; software as a service (SAAS) services featuring software for use in generating, analyzing, and accessing data via artificial intelligence and machine learning; providing an online non-downloadable computer software platform for discovering proteins and drugs, forecasting potential uses of proteins and drug compounds and generating insights from screening and analyzing molecules, featuring software using artificial intelligence and machine learning; providing temporary use of non-downloadable computer software for discovering proteins and drugs, forecasting potential uses of proteins and drug compounds and generating insights from screening and analyzing molecules, all using artificial intelligence and machine learning; software as a service (SAAS) services featuring software for discovering proteins and drugs, forecasting potential uses of proteins and drug compounds and generating insights from screening and analyzing molecules, all using artificial intelligence and machine learning; providing an online non-downloadable computer software platform for analyzing molecular data; providing temporary use of non-downloadable computer software for generating and analyzing molecular data for biotechnology and pharmaceutical companies; software as a service (SAAS) services featuring software for generating and analyzing molecular data for biotechnology and pharmaceutical companies; preclinical drug discovery and development services used for identifying, designing, and optimizing chemical and biological compounds; pharmaceutical evaluation and preclinical evaluation of biological and chemical series and biological and chemical compounds in drug discovery; pharmaceutical drug development and discovery services, namely, identifying, designing, optimizing, and developing biological and chemical series and biological and chemical compounds via software using artificial intelligence and machine learning; providing an online searchable database in the fields of proteins and pharmaceuticals for scientific research purposes, in particular, pharmaceutical research and development, scientific research and development of proteins and pharmaceutical preparations, scientific development of new uses for proteins and pharmaceutical compounds, and scientific technical research; scientific research and development for forecasting the use of molecules as diagnostics, prognostics, and drug compounds and developing new uses for pharmaceutical compounds; research and development in the field of drug discovery and development, diagnostics and prognostics; drug discovery services, namely, discovering novel molecules to develop into drug compounds; medical research and development in the field of biopharmaceuticals, diagnostics, prognostics, and protein engineering

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 30, 2026 EXRA
SOU EXTENSION 1 GRANTED
May 29, 2026 EX1G
SOU EXTENSION 1 FILED
May 29, 2026 EXT1
SOU TEAS EXTENSION RECEIVED
May 29, 2026 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 2, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 7, 2025 NPUB
PUBLISHED FOR OPPOSITION
Oct 7, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 1, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 4, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 11, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 11, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 11, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 13, 2025 GNRN
NON-FINAL ACTION E-MAILED
May 13, 2025 GNRT
NON-FINAL ACTION WRITTEN
May 13, 2025 CNRT
ASSIGNED TO EXAMINER
May 8, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 26, 2025 NWOS
NEW APPLICATION ENTERED
Nov 12, 2024 NWAP